Abnormal Apoptosis of Autoimmunity from Chronic Lymphocytic Leukaemia

Introduce: Apoptosis, with roll in the scheduling of cell life, is a normal process different from cell necrosis, which occurs due to physical or chemical aggression.The decision to activate a suicide process is made based on intrinsic or extrinsic apoptotic messages.The extrinsic ways which inducer apoptosis are ligands and cytokines for death receptors, (DR-Death receptors), being on each cell surface.The intrinsic ways which inducer apoptosis come from the mitochondria or nucleus.Proapoptotic signals, which promote or cause apoptosis, participate in a cascade that leads to the culmination cleavage of a set of proteins, resulting in the disassembly of the cells for apoptosis.Aim: The scope of this review is to emphasise that massive apoptosis overloading the phagocytic capacity can trigger an autoimmune reaction through the presentation of nucleosomes to the immune system.Methods: A large cohort study of cases with the primary Chronic Lymphocytic Leukemia, (CLL), examined samples from more than 100 patients for response to MDM2 protein inhibition and found a direct correlation between wild-type P53 status and MDM2 inhibitor, Nutlin-3, which induced a cytotoxicity across various CLL subtypes.In experimental models, disrupting the MDM2-p53 protein interaction restored p53 function and sensitized tumours to chemotherapy or radiotherapy.This response was not presented in malignant B cells lymphocytes having the expression of ZAP-70 receptor membrane, the expression of CD38 receptor with un-mutated immunoglobulin variable genes and with IGHV and mono-allelic ATM gene loss.Results: Pro-apoptotic signals apoptosis receptors, such as TNF-related apoptosis-inducing ligand, (TRAIL), Tumour Necrosis Factor, (TNF) and Fas receptor, also known as APO-1 or CD95 receptors are the key adaptor proteins transmitting apoptotic signals mediated by the main death receptors, (DRs), known to induce and autophagy process.Also, the autoimmune cytopenia, (AIC), appeared in patients with high-risk CLL (ex, unmutated immunoglobulin heavy chain variable region gene, [IGHV], 17p and 11q deletion).Conclusions: Presented research are impact on the clinical management of patients and requires an attitude adjustment therapeutic adequate in a personalized medicine.